Conatus Pharmaceuticals Company Profile (NASDAQ:CNAT)

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: CNAT
CUSIP:

Key Metrics:

Previous Close: $2.11
50 Day Moving Average: $1.91
200 Day Moving Average: $2.23
52-Week Range: $1.40 - $6.02
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -1.64
P/E Growth: -0.04
Market Cap: $46.57M
Outstanding Shares: 22,072,000
Beta: 0.82

Profitability:

Return on Equity: -77.44%
Return on Assets: -67.94%

Debt:

Debt-to-Equity Ratio: 0.04%
Current Ratio: 9.62%
Quick Ratio: 9.62%

Additional Links:

Companies Related to Conatus Pharmaceuticals:

Consensus Ratings for Conatus Pharmaceuticals (NASDAQ:CNAT) (?)

Ratings Breakdown:	1 Hold Rating, 5 Buy Ratings
Consensus Rating:	Buy (Score: 2.83)
Consensus Price Target:	$9.67 (358.14% upside)

Analysts' Ratings History for Conatus Pharmaceuticals (NASDAQ:CNAT)

Show:

Date	Firm	Action	Rating	Price Target
8/30/2016	FBR & Co	Reiterated Rating	Outperform	$16.00
8/5/2016	Brean Capital	Set Price Target	Buy	$7.00
7/1/2016	Roth Capital	Initiated Coverage	Buy -> Buy
11/17/2015	JMP Securities	Lower Price Target	Market Outperform	$10.00 -> $6.00
11/5/2015	Stifel Nicolaus	Lower Price Target	Buy	$11.00 -> $9.00
9/24/2015	Piper Jaffray Cos.	Reiterated Rating	Hold	$5.00
9/22/2015	HC Wainwright	Initiated Coverage	Buy	$15.00
3/6/2015	MLV & Co.	Set Price Target	Buy	$16.00

(Data available from 9/24/2014 forward)

Earnings History for Conatus Pharmaceuticals (NASDAQ:CNAT)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
11/2/2016
8/3/2016	Q216	($0.38)	($0.30)	View	N/A
5/5/2016	Q116	($0.35)	($0.35)	View	N/A
3/9/2016	Q4	($0.37)	($0.30)	View	Listen
11/4/2015	Q315	($0.38)	($0.31)	View	N/A
8/5/2015	Q215	($0.34)	($0.31)	View	N/A
5/7/2015	Q115	($0.38)	($0.38)	View	Listen
3/11/2015	Q414	($0.49)	($0.34)	View	Listen
11/12/2014	Q3	($0.44)	($0.42)	View	N/A
8/13/2014	Q214	($0.40)	($0.34)	View	Listen
5/13/2014	Q1	($0.33)	($0.34)	View	N/A
3/27/2014		($0.27)	($0.33)	View	N/A
11/14/2013	Q3	($0.20)	($0.28)	View	Listen

(Data available from 1/1/2011 forward)

Earnings Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Current Year EPS Consensus Estimate: $-1.3 EPS
Next Year EPS Consensus Estimate: $-1.29 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	3	($0.44)	($0.33)	($0.37)
Q2 2016	3	($0.43)	($0.35)	($0.38)
Q3 2016	3	($0.39)	($0.32)	($0.36)
Q4 2016	3	($0.41)	($0.26)	($0.34)

(Data provided by Zacks Investment Research)

Dividend History for Conatus Pharmaceuticals (NASDAQ:CNAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Conatus Pharmaceuticals (NASDAQ:CNAT)

Insider Ownership Percentage: 28.50%
Institutional Ownership Percentage: 22.80%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
4/8/2015	Daniel L Kisner	Director	Buy	4,000	$5.75	$23,000.00
7/30/2013	David F Hale	Director	Buy	2,588	$11.00	$28,468.00
7/30/2013	Luke Evnin	Major Shareholder	Buy	165,265	$11.00	$1,817,915.00
7/30/2013	Steven J Mento	CEO	Buy	13,800	$11.00	$151,800.00

(Data available from 1/1/2013 forward)

Latest Headlines for Conatus Pharmaceuticals (NASDAQ:CNAT)

Date	Headline
	What is the Street Saying About Conatus Pharmaceuticals Inc ... - Frisco Fastball (NASDAQ:CNAT) friscofastball.com - September 23 at 3:42 PM
	Keen Investors Find News on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Duncan Research (NASDAQ:CNAT) www.duncanindependent.com - September 23 at 3:42 PM
	Volatile Stocks Under Street Updates: UnitedHealth Group Incorporated (NYSE:UNH), Conatus Pharmaceuticals Inc ... - Street Wise Report (press release) (blog) (NASDAQ:CNAT) streetwisereport.com - September 22 at 4:27 PM
	Penny Stock Investors Keen on Shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Duncan Research (NASDAQ:CNAT) www.duncanindependent.com - September 22 at 4:27 PM
	Top Biotechnology Stock Picking: Tobira Therapeutics, Inc. (TBRA), Conatus Pharmaceuticals Inc. (CNAT) - The Independent Republic (NASDAQ:CNAT) theindependentrepublic.com - September 22 at 4:27 PM
	Biotech Stocks Worth a Closer Look: Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), Tokai Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:CNAT) voiceregistrar.com - September 22 at 4:27 PM
	Why Collegium Pharmaceuticals Inc (COLL), Galmed Pharmaceuticals Ltd (GLMD) and Three Other Stocks Are Registering Significant Gains Today (NASDAQ:CNAT) www.insidermonkey.com - September 22 at 4:27 PM
	Active Stocks Climbing Today – OBAS, FNCX, NAII, GLMD, WINT, MCRB, DTSI (NASDAQ:CNAT) www.fxpips.com - September 22 at 9:55 AM
	5 Biotech Stocks to Watch as Interest in NASH Increases (NASDAQ:CNAT) finance.yahoo.com - September 22 at 9:55 AM
	18 Stocks Moving In Tuesday's Pre-Market Session - Benzinga (NASDAQ:CNAT) www.benzinga.com - September 21 at 4:55 PM
	Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) emricasan, was discovered to be potentially useful in treating the Zika ... - Inside Trade (NASDAQ:CNAT) insidetrade.co - September 21 at 4:55 PM
	Similar Considerations For Galmed Pharmaceuticals Ltd, Conatus Pharmaceuticals Inc, Intercept Pharmaceuticals Inc ... - TCC (NASDAQ:CNAT) www.thecountrycaller.com - September 21 at 4:55 PM
	Pre-Open Stock Movers 09/20: (TBRA) (CNAT) (WINT) Higher; (ASNA) (MGT) (SEAS) Lower (more…) – StreetInsider.com (NASDAQ:CNAT) news.xfoor.com - September 21 at 8:21 AM
	Nasdaq Composite Index Looks Calm on Surface but One Stock Gained +720% Today (NASDAQ:CNAT) www.economiccalendar.com - September 21 at 8:21 AM
	Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal (NASDAQ:CNAT) www.wsj.com - September 21 at 8:21 AM
	Pre-Open Stock Movers 09/20: (TBRA) (CNAT) (WINT) Higher; (ASNA) (MGT) (SEAS) Lower (more...) (NASDAQ:CNAT) www.streetinsider.com - September 21 at 8:21 AM
	[$$] Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal (NASDAQ:CNAT) www.wsj.com - September 21 at 8:21 AM
	Whats Hot Today: Facebook Inc (NASDAQ:FB), Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), Alphabet Inc ... - KC Register (NASDAQ:CNAT) www.kcregister.com - September 17 at 9:03 AM
	Stock Update on Earnings & Estimates for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Frisco Fastball (NASDAQ:CNAT) friscofastball.com - September 16 at 5:30 AM
	Analysts Place Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Under the Lens of the Microscope - Post News (NASDAQ:CNAT) www.kentuckypostnews.com - September 15 at 4:41 PM
	Analysts Place Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Under the Lens of the Microscope - Post News (NASDAQ:CNAT) www.kentuckypostnews.com - September 15 at 4:41 PM
	Sell-side is Weighing in on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Earnings - Frisco Fastball (NASDAQ:CNAT) friscofastball.com - September 15 at 4:41 PM
	Sell-side is Weighing in on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Earnings - Frisco Fastball (NASDAQ:CNAT) friscofastball.com - September 15 at 4:41 PM
	What are Analysts Expecting for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Earnings? - Frisco Fastball (NASDAQ:CNAT) friscofastball.com - September 14 at 9:32 PM
	Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) topped earnings-per-share estimates 50% of the time - The Independent Republic (NASDAQ:CNAT) theindependentrepublic.com - September 8 at 8:00 AM
	Placing Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Shares Under the Microscope - Post News (NASDAQ:CNAT) www.kentuckypostnews.com - September 8 at 8:00 AM
	Traders Are Watching: Conatus Pharmaceuticals Inc. (NASDAQ ... - KC Register (NASDAQ:CNAT) www.kcregister.com - September 7 at 4:20 PM
	Stock Gapping Up Pre-Market: Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Post News (NASDAQ:CNAT) www.kentuckypostnews.com - September 1 at 4:12 PM
	Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) Outperform Rating Reiterated at FBR & Co - BNB Daily (blog) (NASDAQ:CNAT) www.baseball-news-blog.com - September 1 at 4:12 PM
	Conatus (CNAT) Surges on Liver Drug’s Potential Zika Effect (NASDAQ:CNAT) www.economiccalendar.com - August 30 at 4:18 PM
	Why The Zika News Might Not Be So Great For Conatus Pharmaceuticals Inc (CNAT) (NASDAQ:CNAT) www.insidermonkey.com - August 30 at 4:18 PM
	[$$] Potential Zika Virus Therapies Identified by Researchers (NASDAQ:CNAT) www.wsj.com - August 29 at 9:33 PM
	Shares Climbing Higher in Session: Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Post News (NASDAQ:CNAT) www.kentuckypostnews.com - August 29 at 4:30 PM
	Conatus Pharmaceuticals (CNAT) Stock Surges, Liver Drug Could Treat Zika (NASDAQ:CNAT) www.thestreet.com - August 29 at 4:30 PM
	Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH (NASDAQ:CNAT) www.prnewswire.com - August 29 at 8:59 AM
	Is it Time to Buy Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)? The Consensus Is In - Post News (NASDAQ:CNAT) www.kentuckypostnews.com - August 25 at 9:15 AM
	Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:CNAT) www.investornewswire.com - August 23 at 4:25 PM
	Street Consensus on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Post News (NASDAQ:CNAT) www.kentuckypostnews.com - August 20 at 7:29 AM
	Will Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Hit $17 Price Target? - Investor Newswire (NASDAQ:CNAT) www.investornewswire.com - August 17 at 4:27 PM
	CONATUS PHARMACEUTICALS INC. Financials (NASDAQ:CNAT) finance.yahoo.com - August 13 at 4:16 PM
	Stock Update on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Duncan Research (NASDAQ:CNAT) www.duncanindependent.com - August 11 at 10:07 PM
	CONATUS PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:CNAT) biz.yahoo.com - August 5 at 4:21 PM
	Conatus Pharmaceuticals Inc.: Conatus Pharmaceuticals Reports Second Quarter 2016 Financial Results and Program Updates (NASDAQ:CNAT) www.twst.com - August 4 at 11:34 AM
	Conatus (CNAT) Posts Narrower Q2 Loss, Emricasan in Focus (NASDAQ:CNAT) www.zacks.com - August 4 at 11:34 AM
	Conatus reports 2Q loss (NASDAQ:CNAT) sg.finance.yahoo.com - August 3 at 9:57 PM
	Conatus Pharmaceuticals Reports Second Quarter 2016 Financial Results and Program Updates (NASDAQ:CNAT) finance.yahoo.com - August 3 at 4:24 PM
	CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:CNAT) biz.yahoo.com - August 3 at 4:23 PM
	Q2 2016 Conatus Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:CNAT) biz.yahoo.com - August 3 at 11:00 AM
	Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain? (NASDAQ:CNAT) finance.yahoo.com - August 2 at 9:05 AM
	Conatus Pharmaceuticals to Report Second Quarter 2016 Financial Results - GlobeNewswire (press release) (NASDAQ:CNAT) globenewswire.com - July 27 at 12:53 PM